EUVIMEDEUVIMED entdecken
Multizentrische StudieVergleichsstudie

Real‐world comparison of cabozantinib and sunitinib in advanced non‐clear cell renal cell carcinoma: A multicenter study by the Turkish Oncology Group

Gökhan Şahin iD, Esmanur Kaplan Tüzün iD, Halil G Güzel iD, Murad Guliyev iD, Ahmet K Dişli iD, Melike Yazıcı iD, Oğuzhan Yıldız iD, Tuğçe K Güneş iD, Süleyman Alkan iD, Emir G Kahraman iD, Gamze Serin Özel iD, Mehmet C İçli iD und 48 weitere

International Journal of Cancer · 2026

DOI: 10.1002/ijc.70165 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Journal of Cancer, 2026. Verfasst von Gökhan Şahin und 59 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Ege University Faculty of Medicine, Izmir, Turkey. Hauptthemen laut MEDLINE: Sunitinib, Carcinoma, Renal Cell, Kidney Neoplasms, Pyridines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Non‐clear cell renal cell carcinoma (nccRCC) comprises a heterogeneous group of malignancies with limited prospective data and no established first‐line standard. We conducted a multicenter retrospective study across 29 centers in Turkey, including patients with advanced or metastatic nccRCC treated with first‐line cabozantinib or sunitinib between 2015 and 2025. Among 268 patients (sunitinib, n = 198; cabozantinib, n = 70), baseline characteristics were balanced. Cabozantinib was associated with significantly longer median progression‐free survival (PFS) compared to sunitinib (9.2 vs. 6.6 months; HR: 0.66; p = .027), while overall survival (OS) was similar (18.6 vs. 17.2 months; p = .566). Objective response rate (ORR) was higher with cabozantinib (38.6% vs. 26.3%; p = .052). Multivariate analyses identified ECOG performance status ≥2, IMDC risk category, sarcomatoid differentiation, and chromophobe histology as independent prognostic factors for OS. Predictors of PFS included IMDC risk, sarcomatoid features, nephrectomy status, and histologic subtype. These findings suggest that cabozantinib may offer improved disease control over sunitinib in this diverse patient population and provide valuable real‐world insights for therapeutic decision‐making in the absence of prospective randomized data.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SunitinibCarcinoma, Renal CellKidney NeoplasmsPyridinesAnilidesHumansMaleFemaleMiddle AgedAgedRetrospective StudiesAdultTurkeyAged, 80 and overProgression-Free SurvivalPrognosis

Stichwörter der Autor:innen

cabozantinibnon‐clear cell renal cell carcinomareal‐world datasunitinibsurvival outcomes

Substanzen

cabozantinibSunitinibPyridinesAnilides

Autor:innen und Institutionen

  • Department of Medical Oncology, Ege University Faculty of Medicine, Izmir, Turkey.
  • Department of Medical Oncology, Gülhane Training and Research Hospital, Ankara, Turkey.
  • Department of Medical Oncology, Antalya Training and Research Hospital, Antalya, Turkey.
  • Department of Medical Oncology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey.
  • Department of Medical Oncology, Erciyes University Faculty of Medicine, Kayseri, Turkey.
  • Department of Medical Oncology, Kocaeli University Faculty of Medicine, Kocaeli, Turkey.

ORCID-Profile: Gökhan Şahin, Esmanur Kaplan Tüzün, Halil G Güzel, Murad Guliyev, Ahmet K Dişli, Melike Yazıcı, Oğuzhan Yıldız, Tuğçe K Güneş, Süleyman Alkan, Emir G Kahraman, Gamze Serin Özel, Mehmet C İçli, Elif Şahin, Harun Muğlu, Caner Acar, Salih Tunbekici, Haydar Ç Yüksel, Burcu Ulaş Kahya, Sait Kitaplı, Elif Sertesen Çamöz, Derya Kıvrak Salim, Özkan Alan, Ertuğrul Bayram, Cengiz Karaçin, Zeynep G Güç, Ferhat Ekinci, Melek Karakurt Eryılmaz, Hüseyin S Semiz, Olçun Ü Ünal, Sema Sezgin Göksu, Banu Öztürk, Mevlüde İnanç, Kazım Uygun, İlhan Hacıbekiroğlu, Vehbi Erçolak, İsmail O Kara, Ozan Yazıcı, Ahmet Bilici, Özgür Tanrıverdi, Burçak Karaca, Mustafa Erman, Erhan Gökmen, Erdem Göker

Zitieren

APA

Şahin, G., Tüzün, E. K., Güzel, H. G., Guliyev, M., Dişli, A. K., Yazıcı, M., Yıldız, O., Güneş, T. K., Alkan, S., Kahraman, E. G., Özel, G. S., İçli, M. C., Şahin, E., Muğlu, H., Acar, C., Tunbekici, S., Yüksel, H. Ç., Yücel, H., Kahya, B. U., …, & Göker, E. (2026). Real‐world comparison of cabozantinib and sunitinib in advanced non‐clear cell renal cell carcinoma: A multicenter study by the Turkish Oncology Group. International Journal of Cancer. https://doi.org/10.1002/ijc.70165

Vancouver

Şahin G, Tüzün EK, Güzel HG, Guliyev M, Dişli AK, Yazıcı M, et al. Real‐world comparison of cabozantinib and sunitinib in advanced non‐clear cell renal cell carcinoma: A multicenter study by the Turkish Oncology Group. International Journal of Cancer. 2026. doi:10.1002/ijc.70165

BibTeX
@article{ahin2026,
  author = {Şahin, Gökhan and Tüzün, Esmanur Kaplan and Güzel, Halil G and Guliyev, Murad and Dişli, Ahmet K and Yazıcı, Melike and Yıldız, Oğuzhan and Güneş, Tuğçe K and Alkan, Süleyman and Kahraman, Emir G and Özel, Gamze Serin and İçli, Mehmet C and Şahin, Elif and Muğlu, Harun and Acar, Caner and Tunbekici, Salih and Yüksel, Haydar Ç and Yücel, Hakan and Kahya, Burcu Ulaş and Kitaplı, Sait and Büyükşimşek, Mahmut and İpek, Şüheda A and Dama, Pınar E and Usta, Ekin Akyıldız and Yılmaz, Mesut and Aşık, Esra and Özalp, Faruk R and Savsar, Mehmet G and Kocaaslan, Erkam and Sim, Saadet and Ağaoğlu, Ahmet B and Çamöz, Elif Sertesen and Demir, Teyfik and Uyar, Galip C and Yıldırım, Atila and Çınkır, Havva Y and Salim, Derya Kıvrak and Doğu, Gamze Gököz and Alan, Özkan and Bayram, Ertuğrul and Karaçin, Cengiz and Güç, Zeynep G and Ekinci, Ferhat and Eryılmaz, Melek Karakurt and Semiz, Hüseyin S and Ünal, Olçun Ü and Göksu, Sema Sezgin and Öztürk, Banu and İnanç, Mevlüde and Uygun, Kazım and Hacıbekiroğlu, İlhan and Erçolak, Vehbi and Kara, İsmail O and Yazıcı, Ozan and Bilici, Ahmet and Tanrıverdi, Özgür and Karaca, Burçak and Erman, Mustafa and Gökmen, Erhan and Göker, Erdem},
  title = {Real‐world comparison of cabozantinib and sunitinib in advanced non‐clear cell renal cell carcinoma: A multicenter study by the Turkish Oncology Group},
  journal = {International Journal of Cancer},
  year = {2026},
  doi = {10.1002/ijc.70165}
}
Kostenlos starten →